Zydus Lifesciences Ltd - 532321 - USFDA Inspection
USFDA Inspection29-09-2022
Zydus Lifesciences Ltd - 532321 - Closure of Trading Window
Intimation of Closure of Trading Window27-09-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Acquisition of further stake in AMP Energy Green Nine Private Limited22-09-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate22-09-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY(r)20-09-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus launches Lenalidomide Capsules20-09-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated September 16, 2022 titled 'Zydus receives tentative approval from the USFDA for Sugammadex Injection'16-09-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate14-09-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the Company is going to participate in INCred Investor Conference 2022 virtually on September 14, 202214-09-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives approval from the USFDA for Lenalidomide Capsules13-09-2022